Table 1.
Characteristics and treatment parameters of patients who received ipCSI
| Case no. | Age (year) | Sex | Histology | Chemotherapy regimen | Total PBT dose [Gy (RBE)] | Acute hematological AE within 4 weeks after CSI | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre CSI | Concurrent CSI | Post CSI | CSI | Intracranial boost | Spinal boost | WBC | Hb | Platelet | ||||
| AYA cases | ||||||||||||
| 1 | 19 | M | GCT | (IFOS-CDDP-VP-16) × 6 | none | none | a23.4 | bnone | 21.6 | Gr. 2 | Gr. 2 | Gr. 0 |
| 2 | 16 | M | GCT | (IFOS-CDDP-VP-16) × 1 | none | (IFOS-CDDP-VP-16) × 5 | 30.6 | 30.6 | none | Gr. 0 | Gr. 1 | Gr. 0 |
| 3 | 17 | F | GCT | (IFOS-CDDP-VP-16) × 1 | none | (IFOS-CDDP-VP-16) × 5 | 30.6 | 30.6 | none | Gr. 0 | Gr. 0 | Gr. 0 |
| 4 | 17 | M | MB | none | (IFOS-CDDP-VP-16) × 1 | (IFOS-CDDP-VP-16) × 5 | 23.4 | 32.4 | none | Gr. 3 | Gr. 1 | Gr. 1 |
| Patients < 15 years of age | ||||||||||||
| 5 | 9 | F | MB | none | (CBDCA-VCR) × 1 | (CPM-VCR) × 6 | 36.0 | 19.8 | none | Gr. 3 | Gr. 3 | Gr. 2 |
| 6 | 10 | M | MB | none | none | n/a | 23.4 | 30.6 | none | Gr. 2 | Gr. 1 | Gr. 0 |
| 7 | 9 | M | MB | (VCR-CDDP-VP-16-CPM) × 3(CBDCA-Thio + PBSCR) × 3 | none | n/a | 36.0 | 18.0 | 9.0 | Gr. 2 | Gr. 1 | Gr. 1 |
| 8 | 7 | F | MB | none | none | n/a | 23.4 | 30.6 | none | Gr. 2 | Gr. 0 | Gr. 1 |
| 9 | 11 | M | MB | none | VCR × 1 | (CDDP-VCR-CPM) × 8 | 23.4 | 32.4 | none | Gr. 3 | Gr. 2 | Gr. 0 |
aOnly whole-spinal irradiation conducted. bWhole-cranial irradiation of 25.2 Gy in 14 fractions and boost irradiation of 19.8 Gy in 11 fractions using photon beams 6 years before PBT. PBT = proton beam therapy, RBE = relative biological effectiveness, CSI = craniospinal irradiation, ipCSI = intensity-modulated proton craniospinal irradiation, AE = adverse events, M = male, F = female, WBC = white blood cell, Hb = hemoglobin, AYA = adolescent and young adult, Gr. = Grade, GCT = germ cell tumor, MB = medulloblastoma, IFOS = ifosfamide, CDDP = cisplatin, VP-16 = etoposide, VCR = vincristine, CPM = cyclophosphamide, CBDCA = carboplatin, Thio = thio-TEPA, PBSCR = peripheral blood stem cell rescue.